Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
PROVECTUS BIOPHARMACEUTICALS, INC.
Next earnings ≈ Aug 13, 2026 · est. from filing cadence
High return on equity (86.2%); but revenue fell -45.5% YoY.
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
PROVECTUS BIOPHARMACEUTICALS, INC. shows $336K in FY2025 revenue (-45.5% YoY), a -1615.8% net margin, and 86.2% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0000315545, latest 10-Q filed 2026-05-14) · EODHD · rules-based read · as of 6/18/2026, 1:07:44 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $989K | $558K | $617K | $336K |
| Gross profit | — | — | — | — | — |
| Operating income | -$4.67M | -$3.43M | -$2.90M | -$4.53M | -$5.29M |
| Net income | -$5.54M | -$3.55M | -$3.10M | -$4.73M | -$5.43M |
| Diluted EPS | — | -$0.01 | -$0.01 | -$0.01 | -$0.01 |
| Net margin | — | -359.4% | -556.2% | -766.9% | -1615.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median